MX2023005940A - Radioinmunoterapia con her3 para el tratamiento de canceres solidos. - Google Patents
Radioinmunoterapia con her3 para el tratamiento de canceres solidos.Info
- Publication number
- MX2023005940A MX2023005940A MX2023005940A MX2023005940A MX2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A MX 2023005940 A MX2023005940 A MX 2023005940A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- her3
- solid cancer
- radioimmunotherapy
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116225P | 2020-11-20 | 2020-11-20 | |
| US202063118181P | 2020-11-25 | 2020-11-25 | |
| US202163226699P | 2021-07-28 | 2021-07-28 | |
| US202163250725P | 2021-09-30 | 2021-09-30 | |
| PCT/US2021/056259 WO2022087416A1 (en) | 2020-10-22 | 2021-10-22 | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| PCT/US2021/060370 WO2022109404A1 (en) | 2020-11-20 | 2021-11-22 | Her3 radioimmunotherapy for the treatment of solid cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005940A true MX2023005940A (es) | 2023-07-27 |
Family
ID=81709768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005940A MX2023005940A (es) | 2020-11-20 | 2021-11-22 | Radioinmunoterapia con her3 para el tratamiento de canceres solidos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4247430A4 (enExample) |
| JP (1) | JP2023550462A (enExample) |
| KR (1) | KR20230128271A (enExample) |
| AU (1) | AU2021382717A1 (enExample) |
| CA (1) | CA3199259A1 (enExample) |
| IL (1) | IL303030A (enExample) |
| MX (1) | MX2023005940A (enExample) |
| WO (1) | WO2022109404A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023546679A (ja) * | 2020-10-22 | 2023-11-07 | アクティニウム ファーマシューティカルズ インコーポレイテッド | がん治療における放射免疫療法とｃｄ４７遮断の併用 |
| JP2024528081A (ja) * | 2021-07-28 | 2024-07-26 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 癌の治療における放射免疫療法及びｃｄ４７遮断薬の組み合わせ |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2422291C (en) * | 2000-09-15 | 2011-03-08 | Sloan-Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| AU2010284018C1 (en) * | 2009-08-21 | 2015-10-15 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of ErbB3 and uses thereof |
| AU2011286407A1 (en) * | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
| JP2018524373A (ja) * | 2015-07-15 | 2018-08-30 | ザイムワークス，インコーポレイテッド | 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト |
| US20220008570A1 (en) * | 2018-12-21 | 2022-01-13 | Actinium Pharmaceuticals, Inc. | Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer |
-
2021
- 2021-11-22 EP EP21895766.0A patent/EP4247430A4/en active Pending
- 2021-11-22 JP JP2023530591A patent/JP2023550462A/ja active Pending
- 2021-11-22 MX MX2023005940A patent/MX2023005940A/es unknown
- 2021-11-22 AU AU2021382717A patent/AU2021382717A1/en active Pending
- 2021-11-22 IL IL303030A patent/IL303030A/en unknown
- 2021-11-22 CA CA3199259A patent/CA3199259A1/en active Pending
- 2021-11-22 WO PCT/US2021/060370 patent/WO2022109404A1/en not_active Ceased
- 2021-11-22 KR KR1020237020749A patent/KR20230128271A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023550462A (ja) | 2023-12-01 |
| WO2022109404A1 (en) | 2022-05-27 |
| AU2021382717A9 (en) | 2025-03-13 |
| KR20230128271A (ko) | 2023-09-04 |
| AU2021382717A1 (en) | 2023-07-06 |
| EP4247430A4 (en) | 2024-12-11 |
| IL303030A (en) | 2023-07-01 |
| EP4247430A1 (en) | 2023-09-27 |
| CA3199259A1 (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| King et al. | Use of amifostine for cytoprotection during radiation therapy: a review | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
| MX2022005596A (es) | Regimen de dosificacion para agentes anti-dll3. | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| MX2020006808A (es) | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. | |
| JP2016515586A5 (enExample) | ||
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| CL2022000458A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604) | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| MX391965B (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| Wong | Total marrow irradiation: redefining the role of radiotherapy in bone marrow transplantation | |
| Vo et al. | Safety and efficacy of yttrium-90-labeled anti-CD45 antibody (90Y-DOTA-BC8) followed by a standard reduced-intensity hematopoietic stem cell transplant (HCT) regimen for patients with refractory/relapsed leukemia or high-risk myelodysplastic syndrome (MDS) | |
| ZA202401639B (en) | Small molecule inhibitors for anti-cancer combination therapy | |
| EA200801670A1 (ru) | Комбинированная противораковая терапия с перфузией изолированного органа | |
| WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer | |
| JP2019509329A5 (enExample) |